Effect of Bevacizumab, a Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor, on Peritoneal Metastasis of MNK-45P Human Gastric Cancer in Mice

Journal of Surgical Research

Volumn 154, Issue 2, 2009, Pages 196-202

  Ninomiya, Shigeo ^a   Inomata, Masafumi ^a   Tajima, Masaaki ^a   Ali, Anwar Tawik ^a   Ueda, Yoshitake ^a   Shiraishi, Norio ^a   Kitano, Seigo ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

bevacizumab; gastric cancer; peritoneal metastasis

Indexed keywords

BEVACIZUMAB; MESSENGER RNA; VASCULOTROPIN;

ABDOMEN; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; ASCITES TUMOR; CANCER CELL CULTURE; CANCER MODEL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; METASTASIS INHIBITION; MOUSE; NONHUMAN; PERITONEUM METASTASIS; PRIORITY JOURNAL; STOMACH CANCER; TUMOR VASCULARIZATION; TUMOR VOLUME;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PERITONEAL NEOPLASMS; STOMACH NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67349196067     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2008.08.017     Document Type: Article

References (39)

1. Kimura K. Gastritis and gastric cancer. Asia. Gastroenterol Clin North Am 29 (2000) 609
2. Benevolo M., Mottolese M., Cosimelli M., et al. Diagnostic and prognostic value of peritoneal immunocytology in gastric cancer. J Clin Oncol 16 (1998) 3406
3. Folkman J. What is the evidence that tumors are angiogenesis-dependent?. J Nat Cancer Inst 82 (1990) 4
4. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1 (1995) 27
5. Mori A., Arii S., Furutani M., et al. Soluble Flt-1 gene therapy for peritoneal metastases using HVJ-cationic liposomes. Gene Ther 7 (2000) 1027
6. Yabushita H., Shimazu M., Noguchi M., et al. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer. Oncol Rep 10 (2003) 89
7. Shaheen R.M., Ahmad S.A., Liu W., et al. Inhibition growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 85 (2001) 584
8. Kraft A., Weindel K., Ochs A., et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 85 (1999) 178
9. Zebrowski B.K., Liu W., Ramirez K., et al. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 6 (1999) 373
10. Kim K.J., Li B., Winer J., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature (London) 362 (1993) 841
11. Asano M., Yukita A., Matsumoto T., et al. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor. Cancer Res 55 (1995) 5296
12. Kanai T., Konno H., Tanaka T., et al. Anti-tumor and anti-metastatic effect of human-vascular endothelial-growth factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice. Int J Cancer 77 (1998) 933
13. Kabbinavar F., Hurwitz H., Fehrenbacher L., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil/leucovorin with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 (2003) 60
14. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335
15. Hurwitz H., Fehrenbacher L., Hainsworth J.D., et al. Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23 (2005) 3502
16. Chen H.X., Mooney M., Boron M., et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: An NCI treatment referral center trial TRC-0301. J Clin Oncol 24 (2006) 3354
17. Miller K.D., Chap L.I., Holmes F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 (2005) 792
18. Ramaswamy B., Elias A.D., Kelbick N.T., et al. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res 12 (2006) 3124
19. Johnson D.H., Fehrenbacher L., Novotny W.F., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22 (2004) 2184
20. Yada K., Shibata K., Matsumoto T., et al. Protease-activated receptor-2 regulates cell proliferation and enhances cyclooxygenase-2 mRNA expression in human pancreatic cancer cells. J Surg Oncol 89 (2005) 79
21. Iimura H., Maruyama K., Okinaga K., et al. Intracellular targeting therapy of cisplatin-encapsulated transferring-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int J Cancer 99 (2002) 130
22. Matsui Y., Inomata M., Tojigamori M., et al. Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Int J Oncol 27 (2005) 81
23. Hu L., Hofmann J., Holash J., et al. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res 11 (2005) 6966
24. Namiki Y., Namiki T., Yoshida H., et al. Preclinical study of a tailor-made combination of NK-4-expressing gene therapy and gefitinib (ZD1839, Iressa) for disseminated peritoneal scirrhous gastric cancer. Int J Cancer 118 (2006) 1545
25. Sako A., Kitayama J., Shida D., et al. Lysophosphatidic acid (LPA)-induced vascular endothelial growth factor (VEGF) by mesothelial cells and quantification of host-derived VEGF in malignant ascites. J Surg Res 130 (2006) 94
26. Ueda K., Iwahashi M., Matsuura I., et al. Adenoviral-mediated gene transduction of the hepatocyte growth factor (HGF) antagonist, NK4, suppresses peritoneal metastases of gastric cancer in nude mice. Eur J Cancer 40 (2004) 2135
27. Lang S.A., Gaumann A., Koehl G.E., et al. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer 120 (2007) 1803
28. Yamamoto S., Yasui W., Kitadai Y., et al. Expression of vascular endothelial growth factor in human gastric carcinomas. Pathol Int 48 (1998) 499
29. Kamiya K., Konno H., Tanaka T., et al. Antitumor effect on human gastric cancer and induction of apotosis by vascular endothelial growth factor neutralizing antibody. Jpn J Cancer Res 90 (1999) 794
30. Bruns C.J., Shrader M., Harbison M.T., et al. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer 102 (2002) 101
31. Tokuyama J., Kubota T., Saikawa Y., et al. Tyrosine kinase inhibitor SU6668 inhibits peritoneal dissemination of gastric cancer via suppression of tumor angiogenesis. Anticancer Res 25 (2005) 17
32. O'Reilly M.S., Boehm T., Shing Y., et al. Endostatin. An endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277
33. Pourgholami M.H., Cai Z.Y., Lu Y., et al. Albendazole: A potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor bearing nude mice. Clin Cancer Res 12 (2006) 1928
34. Numnum T.M., Rocconi R.P., Whitworth R.J., et al. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol 102 (2006) 425
35. Nagy J.A., Masse E.M., Herzberg K.T., et al. Pathogenesis of ascites tumor growth: Vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 55 (1995) 360
36. Senger D.R., Galli S.J., Dvorak A.M., et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219 (1983) 983
37. Shah M.A., Ramanathan R.K., Ilson D.H., et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24 (2006) 5201
38. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427
39. Emanuel S., Gruninger R.H., Fuentes-Pesquera A., et al. A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models. Mol Pharmacol 66 (2004) 635